This week, a study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis (PrEP).
These restrictions have no proven public-health benefit -- and can, in fact, shroud nations in a false sense of assurance that such bans, and not sound health policy, will keep HIV in their countries.
"Gastrointestinal (GI) health is proving to be a vital, though often ignored, component of HIV infection."
People living with HIV in North America who receive antiretroviral therapy have improving -- near normal, in fact -- life expectancy, according to new data presented at IAS 2013.
Investigators from the NA-ACCORD presented the results of their analys...
Roughly one out of every 13 gay men in a recent study had detectable HIV in their semen but an undetectable viral load in their bloodstream.
Despite generally exciting findings, a new study notes that improvements in life expectancy varied widely by sex, race and other factors.